Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 PUFA Effect on Beta-cell Function in Type 2 Diabetes
ChiCTR2400091599Phase 4Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omega-3-acid ethyl ester in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Central Hospital Affiliated to Shandong First Medical University. Primary endpoints: Plasma docosahexaenoic acid (DHA) levels, Plasma eicosapentaenoic acid (EPA) levels and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
omega-3-acid ethyl ester
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400091599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091599.